Ventilator-associated pneumonia (VAP) due to Acinetobacter spp. is one of the most common infections in the intensive care unit. Hence, we performed this prospective-observational multicenter study, and described the course and outcome of the disease. This study was performed in 24 centers between...
求翻译:Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: A systematic review and meta-analysis是什么意思?待解决 悬赏分:1 - 离问题结束还有 Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-nega...
BackgroundInfections caused by extensive drug-resistant Acinetobacter baumannii (XDR-AB) have been increasingly observed and are associated with a high mortality rate. We present our experience using aerosolized colistin for the treatment of ventilator-associated pneumonia (VAP) due to XDR-AB in neonate...
Introduction: Ventilator-associated pneumonia (VAP) is a distinct clinical entity characterized by an onset after 48 hours of the application of mechanical ventilation (MV). Protocols exist to aid in the prevention of VAP, but this infection carries a devastating impact on patient morbidity and pote...
De-escalation of therapy should be a constant focus in an attempt to reduce overall antibiotic consumption and the selection pressure on ICU flora, thus minimizing the development and spread of antimicrobial resistance in the ICU. 展开 关键词: ventilator-associated pneumonia selective digestive ...
Diagnosis, management and prevention of ventilator-associated pneumonia: an update. Ventilator-associated pneumonia (VAP) affects 10鈥 20% of mechanically ventilated patients and is associated with increased morbidity and mortality and high... JL Vincent,DDS Barros,S Cianferoni - 《Drugs》 被引量: ...
The present study evaluated the effect of de-escalation on ventilator-associated pneumonia (VAP) in trauma patients. This retrospective study was conducted on trauma patients with VAP, who received de-escalation therapy (de-escalation group) or non-de-escalation therapy (non-de-escalation group). ...
Current guidelines for the empiric treatment of ventilator-associated pneumonia (VAP) recommend that vancomycin is dosed 15 mg/kg and administered twice daily for a target trough level of 15 to 20 μg/mL. This study compared conventional intermittent vancomycin infusion (IVI) with continuous vancomy...
BACKGROUND: Experience with intravenous and aerosolized forms of colistin for the treatment of ventilator-associated pneumonia (VAP) in patients without cystic fibrosis is limited. We aimed to assess the safety and efficacy of colistin for the treatment of VAP. METHODS: We searched MEDLINE and Cochr...
- 《Iranian Journal of Clinical Infectious Diseases》 被引量: 17发表: 2009年 Meropenem plus Ertapenem and Ceftazidime–Avibactam plus Aztreonam for the Treatment of Ventilator Associated Pneumonia Caused by Pan-Drug Resistant Klebsi... Introduction: Gram-negative bacteria (GNB) account for about 70%...